Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the development of tests for various types of cancers. The company’s flagship product, Cologuard test is a US FDA-approved non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of colorectal cancer and pre-cancer. It uses a multi-target approach to detect DNA and hemoglobin biomarkers is related to colorectal cancer. The company also offers Oncotype DX gene expression tests for prostate, breast, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test designed for advanced stage prostate cancer. It operates manufacturing and laboratory facilities in Madison, Wisconsin to process Cologuard tests. Exact Sciences is headquartered in Madison, Wisconsin, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Exact Sciences Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Exact Sciences Corp Company Overview
- Exact Sciences Corp Company Snapshot
- Exact Sciences Corp Pipeline Products and Ongoing Clinical Trials Overview
- Exact Sciences Corp - Pipeline Analysis Overview
- Business Description
- Exact Sciences Corp - Key Facts
- Exact Sciences Corp - Major Products and Services
- Exact Sciences Corp Pipeline Products by Development Stage
- Exact Sciences Corp Ongoing Clinical Trials by Trial Status
- Exact Sciences Corp Pipeline Products Overview
- ActiveTargeting Assay
- ActiveTargeting Assay Product Overview
- Blood Based Colorectal Cancer Screening Test
- Blood Based Colorectal Cancer Screening Test Product Overview
- Blood-based Lung Cancer Screening Test
- Blood-based Lung Cancer Screening Test Product Overview
- Cancerguard
- Cancerguard Product Overview
- CancerSEEK Test
- CancerSEEK Test Product Overview
- Circulating Tumor DNA Test - Colorectal Cancer
- Circulating Tumor DNA Test - Colorectal Cancer Product Overview
- Circulating Tumor DNA Test - Colorectal Cancer Clinical Trial
- Cologuard 2.0
- Cologuard 2.0 Product Overview
- Diagnostic Assay - Liver Cancer
- Diagnostic Assay - Liver Cancer Product Overview
- Diagnostic Test - Breast Cancer
- Diagnostic Test - Breast Cancer Product Overview
- Diagnostic Test - Hepatocellular Carcinoma
- Diagnostic Test - Hepatocellular Carcinoma Product Overview
- Diagnostic Test - Lung Cancer
- Diagnostic Test - Lung Cancer Product Overview
- Diagnostic Test - Non Small Cell Lung Cancer
- Diagnostic Test - Non Small Cell Lung Cancer Product Overview
- Diagnostic Test - Prostate Cancer
- Diagnostic Test - Prostate Cancer Product Overview
- DNA Integrity Assay
- DNA Integrity Assay Product Overview
- DNA Methylation Based Blood Test - Cancer
- DNA Methylation Based Blood Test - Cancer Product Overview
- DNA Methylation Based Blood Test - Minimal Residual Disease
- DNA Methylation Based Blood Test - Minimal Residual Disease Product Overview
- Idylla IVD Oncotype DX Breast Recurrence Score Test
- Idylla IVD Oncotype DX Breast Recurrence Score Test Product Overview
- Idylla IVD Oncotype DX Breast Recurrence Score Test Clinical Trial
- Liquid Biopsy Test - Bladder Cancer
- Liquid Biopsy Test - Bladder Cancer Product Overview
- Liquid Biopsy Test - Breast Cancer
- Liquid Biopsy Test - Breast Cancer Product Overview
- Liquid Biopsy Test - Cervical Cancer
- Liquid Biopsy Test - Cervical Cancer Product Overview
- Liquid Biopsy Test - Esophageal Cancer
- Liquid Biopsy Test - Esophageal Cancer Product Overview
- Liquid Biopsy Test - Kidney Cancer
- Liquid Biopsy Test - Kidney Cancer Product Overview
- Liquid Biopsy Test - Lymphoma
- Liquid Biopsy Test - Lymphoma Product Overview
- Liquid Biopsy Test - Melanoma
- Liquid Biopsy Test - Melanoma Product Overview
- Liquid Biopsy Test - Ovarian Cancer
- Liquid Biopsy Test - Ovarian Cancer Product Overview
- Liquid Biopsy Test - Pancreatic Cancer
- Liquid Biopsy Test - Pancreatic Cancer Product Overview
- Liquid Biopsy Test - Prostate Cancer
- Liquid Biopsy Test - Prostate Cancer Product Overview
- Liquid Biopsy Test - Stomach Cancer
- Liquid Biopsy Test - Stomach Cancer Product Overview
- Liquid Biopsy Test - Uterine Cancer
- Liquid Biopsy Test - Uterine Cancer Product Overview
- Liquid Biopsy-Based Bladder Cancer Test
- Liquid Biopsy-Based Bladder Cancer Test Product Overview
- LungVantage Test
- LungVantage Test Product Overview
- Multi-Cancer Earlier Detection Test
- Multi-Cancer Earlier Detection Test Product Overview
- Multi-Cancer Screening Test
- Multi-Cancer Screening Test Product Overview
- Negative Biopsy Test - Prostate Cancer
- Negative Biopsy Test - Prostate Cancer Product Overview
- Next Generation Sequencing Oncotype DX - Prostate Cancer Assay
- Next Generation Sequencing Oncotype DX - Prostate Cancer Assay Product Overview
- Oncofind
- Oncofind Product Overview
- Oncosearch
- Oncosearch Product Overview
- Oncotype Dx - Kidney Cancer
- Oncotype Dx - Kidney Cancer Product Overview
- Oncotype SEQ - Tissue Mutation Panel
- Oncotype SEQ - Tissue Mutation Panel Product Overview
- Oncotype TRACK
- Oncotype TRACK Product Overview
- Oncoverify
- Oncoverify Product Overview
- Oncowatch
- Oncowatch Product Overview
- PapSEEK
- PapSEEK Product Overview
- Prognostic Test - Melanoma
- Prognostic Test - Melanoma Product Overview
- Prognostic Test - Non-Metastatic Renal Cell Carcinoma
- Prognostic Test - Non-Metastatic Renal Cell Carcinoma Product Overview
- Riskguard Minimal Residual Disease Test
- Riskguard Minimal Residual Disease Test Product Overview
- Riskguard Prognosis/Therapy Guidance Test
- Riskguard Prognosis/Therapy Guidance Test Product Overview
- Riskguard Recurrence Monitoring Test
- Riskguard Recurrence Monitoring Test Product Overview
- Riskguard Therapy Selection Test
- Riskguard Therapy Selection Test Product Overview
- TARDIS Test
- TARDIS Test Product Overview
- UroSeqS
- UroSeqS Product Overview
- Viomics Diagnostic Assay - Breast Cancer
- Viomics Diagnostic Assay - Breast Cancer Product Overview
- Viomics Diagnostic Assay - Colon Cancer
- Viomics Diagnostic Assay - Colon Cancer Product Overview
- Viomics Diagnostic Assay - Pancreatic Cancer
- Viomics Diagnostic Assay - Pancreatic Cancer Product Overview
- Exact Sciences Corp - Key Competitors
- Exact Sciences Corp - Key Employees
- Exact Sciences Corp - Key Employee Biographies
- Exact Sciences Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Exact Sciences Corp, Recent Developments
- Jun 21, 2023: Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
- May 09, 2023: Exact Sciences announces Q1 2023 results
- Apr 10, 2023: Exact Sciences schedules first quarter 2023 earnings call
- Jan 08, 2023: Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
- Dec 09, 2022: Exact Sciences presents first time data detailing ability to predict radiation therapy benefit in breast cancer patients
- Sep 10, 2022: Exact Sciences demonstrates power of multi-cancer early detection approach with data presentation at the 2022 European Society for Medical Oncology Congress
- Aug 02, 2022: Exact Sciences Announces Second Quarter 2022 Results
- Aug 02, 2022: Mdxhealth Acquires Oncotype DX GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results
- Jun 21, 2022: Ultima Genomics and Exact Sciences enter long-term supply agreement aimed at improving patient access to genomic testing by driving down sequencing costs
- Apr 26, 2022: Exact Sciences Announces First Quarter 2022 Results
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Exact Sciences Corp Pipeline Products and Ongoing Clinical Trials Overview
- Exact Sciences Corp Pipeline Products by Equipment Type
- Exact Sciences Corp Pipeline Products by Indication
- Exact Sciences Corp Ongoing Clinical Trials by Trial Status
- Exact Sciences Corp, Key Facts
- Exact Sciences Corp, Major Products and Services
- Exact Sciences Corp Number of Pipeline Products by Development Stage
- Exact Sciences Corp Pipeline Products Summary by Development Stage
- Exact Sciences Corp Ongoing Clinical Trials by Trial Status
- Exact Sciences Corp Ongoing Clinical Trials Summary
- ActiveTargeting Assay - Product Status
- ActiveTargeting Assay - Product Description
- Blood Based Colorectal Cancer Screening Test - Product Status
- Blood Based Colorectal Cancer Screening Test - Product Description
- Blood-based Lung Cancer Screening Test - Product Status
- Blood-based Lung Cancer Screening Test - Product Description
- Cancerguard - Product Status
- Cancerguard - Product Description
- CancerSEEK Test - Product Status
- CancerSEEK Test - Product Description
- Circulating Tumor DNA Test - Colorectal Cancer - Product Status
- Circulating Tumor DNA Test - Colorectal Cancer - Product Description
- Circulating Tumor DNA Test - Colorectal Cancer - Clinical Validation Study of Circulating Tumor DNA Test to Detect Minimal Residual Disease in Patients with Colorectal Cancer: CORRECT-MRD II
- Circulating Tumor DNA Test - Colorectal Cancer - CORRECT-MRD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- EDP Biotech Corporation
- Cambridge Epigenetix Ltd
- Nucleix Ltd
- Epigenomics AG
- Grail LLC
- Lineage Cell Therapeutics Inc
- CellMax, Inc.
- Freenome Inc
- Natera Inc
- StageZero Life Sciences Ltd
